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Background: Recently, the high-mobility group A1 gene (HMGA1) variant IVS5-13insC has been associated with
type 2 diabetes, but reported associations are inconsistent and data are lacking in Hispanic and African American
populations. We sought to investigate the HMGA1-diabetes association and to characterize IVS5-13insC allele
frequencies and linkage disequilibrium (LD) in 3,070 Caucasian, Hispanic, and African American patients from the
INternational VErapamil SR-Trandolapril STudy (INVEST).
Methods: INVEST was a randomized, multicenter trial comparing two antihypertensive treatment strategies in an
ethnically diverse cohort of hypertensive, coronary artery disease patients. Controls, who were diabetes-free
throughout the study, and type 2 diabetes cases, either prevalent or incident, were genotyped for IVS5-13insC
using TaqmanW, confirmed with Pyrosequencing and Sanger sequencing. For LD analysis, genotyping for eight
additional HMGA1 single nucleotide polymorphisms (SNPs) was performed using the IlluminaW HumanCVD
BeadChip. We used logistic regression to test association of the HMGA1 IVS5-13insC and diabetes, adjusted for age,
gender, body mass index, and percentage European, African, and Native American ancestry.
Results: We observed IVS5-13insC minor allele frequencies consistent with previous literature in Caucasians and
African Americans (0.03 in cases and 0.04 in controls for both race/ethnic groups), and higher frequencies in Hispanics
(0.07 in cases and 0.07 in controls). The IVS5-13insC was not associated with type 2 diabetes overall (odds ratio 0.98
[0.76-1.26], p=0.88) or in any race/ethnic group. Pairwise LD (r2) of IVS5-13insC and rs9394200, a SNP previously used as
a tag SNP for IVS5-13insC, was low (r2=0.47 in Caucasians, r2=0.25 in Hispanics, and r2=0.06 in African Americans).
Furthermore, in silico analysis suggested a lack of functional consequences for the IVS5-13insC variant.
Conclusions: Our results suggest that IVS5-13insC is not a functional variant and not associated with type 2 diabetes in
an ethnically diverse, hypertensive, coronary artery disease population. Larger, more adequately powered studies need
to be performed to confirm our findings.
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Type 2 diabetes constitutes a major and growing health
problem worldwide and is predicted to afflict 490 million
by 2030 [1]. Type 2 diabetes has strong genetic influences
and many polymorphisms have now been reproducibly
associated with type 2 diabetes [2,3]. However, genome
wide association studies (GWAS) explain only 10-15% of
heritability and have not consistently improved diabetes
risk prediction [4]. Low frequency variation may account
for much of the missing heritability in type 2 diabetes risk
and may help translate genetic association study results
into clinical type 2 diabetes risk prediction.
Recently, the low frequency insertion polymorphism
IVS5-13insC (c.136-14_136-13insC) in the high-mobility
group A1 gene (HMGA1), a transcriptional regulator of
the insulin receptor gene (INSR), was identified and asso-
ciated with type 2 diabetes [5]. Whereas two studies have
observed a significant positive association between IVS5-
13insC and type 2 diabetes in Caucasian and Chinese
populations [5,6], another study in Caucasians observed
no association [7]. Data are lacking for IVS5-13insC in
populations with African and Hispanic descent, which
have disproportionately high type 2 diabetes prevalence
[8]. Conflicting results for an HMGA1 association with
type 2 diabetes and the lack of data in diverse race/ethnic
groups make clinical translation of the HMGA1 IVS5-
13insC genotyping especially difficult.
Evidence for the functional impact of the HMGA1 IVS5-
13insC variant is also conflicting. One study observed that
HMGA1 and INSR expression was decreased in diabetic
carriers of IVS5-13insC versus wild type diabetic and non-
diabetic patients [5]. Additionally, INSR protein expression
and insulin-binding capacity was restored in lymphoblasts
obtained from diabetic IVS5-13insC carriers by HMGA1
DNA transfection. Another study observed no effect of
IVS5-13insC on HMGA1 or INSR expression in adipose
tissue of normoglycemic patients [7]. IVS5-13insC occurs
at position −13 of HMGA1 exon 6, but the direct mechan-
ism of the variant’s effects on mRNA expression or amino
acid sequence remains unclear.
We tested the association of HMGA1 IVS5-13insC with
type 2 diabetes in an ethnically diverse population from
the INternational VErapamil SR-Trandolapril STudy (IN-
VEST). INVEST compared CV outcomes and NOD in
hypertensive coronary artery disease patients treated with
two antihypertensive treatment strategies. We also deter-
mined minor allele frequencies (MAF) and linkage dis-
equilibrium (LD) for HMGA1 variants and tested the
functional impact of IVS5-13insC in silico.
Methods
Study design and participants
INVEST compared CV outcomes and incident diabetes
in hypertensive, coronary artery disease patients at least50 years of age during randomized treatment with either
an atenolol-based or a verapamil sustained release (SR)-
based antihypertensive treatment strategy. The design,
primary outcome, and NOD results have been previously
published in detail [9-12]. Briefly, the verapamil SR strat-
egy consisted of stepped therapy with verapamil SR,
trandolapril add-on, dose titration, then HCTZ add-on
treatment for BP control and end organ protection as
necessary. The atenolol-based strategy consisted of ate-
nolol, HCTZ add-on, dose titration, then trandolapril
add-on treatment as necessary. The INVEST GENEtic
Substudy (INVEST-GENES) collected DNA samples
from 5,979 INVEST patients at 187 sites in the United
States and Puerto Rico.
We conducted a nested case control study including
cases with type 2 diabetes at baseline (prevalent dia-
betes) or type 2 diabetes that developed during a mean
2.8 years follow-up (incident diabetes). Type 2 diabetes
was determined by patient report and by site investiga-
tors from a review of all available patient data, including
use of diabetic medication and lab measures [11]. We
identified age, gender, and race/ethnicity-matched con-
trols who remained diabetes-free over a mean 2.8 years
follow-up. Age matching was performed after stratifica-
tion by decade and we attempted to match cases and
controls in a 1:1 ratio. The institutional review boards of
participating study centers approved the study protocol
and all patients provided written informed consent for
participation in INVEST and additional written informed
consent for genetic studies. INVEST is registered at
clinicaltrials.gov (NCT00133692).
Genotyping
Genotyping for HMGA1 IVS5-13insC was performed
using TaqManW (Applied Biosystems, Foster City, CA,
USA) with PCR primers and probe for IVS5-13insC
(PN4331349) purchased from Applied Biosystems. For
IVS5-13insC genotyping quality control, 5% of samples
were genotyped in duplicate on TaqmanW. A total of 612
Taqman genotypes were confirmed using pyrosequencing
(Biotage AB, Uppsala, Sweden), using the following PCR
and sequencing primers respectively: forward-biotiny-
lated-5′-GGGGTGGAAACAGGTGATG-3′, reverse-5′-C
ACTTCGCTGGGCTCCTT-3′, and reverse-5′-TTCTGT
AAAGACAGAGG-3′. Sanger sequencing was used to
genotype 58 samples that showed discrepancies between
TaqmanW and Pyrosequencing platforms.
Genotyping for eight additional HMGA1 single nu-
cleotide polymorphisms (SNPs) was performed using the
HumanCVD BeadChip and Infinium II Assay (Illumina,
San Diego, CA) on 1,489 INVEST patients to perform
LD analyses. The HumanCVD BeadChip contains ap-
proximately 50,000 cosmopolitan tag SNPs for 2,100 CV
and metabolic-related genes [13]. HumanCVD BeadChip
Karnes et al. Journal of Translational Medicine 2013, 11:12 Page 3 of 6
http://www.translational-medicine.com/content/11/1/12data quality was ensured in PLINK using genotype and
sample call rates, concordance rates for blind duplicates,
gender confirmation, cryptic relatedness using pairwise
identity-by-descent, and estimation of heterozygosity
using the inbreeding coefficient F [14]. Individuals were
excluded if call rates were below 90 percent and SNPs
were excluded if call rates were below 95 percent. In
addition, 87 ancestry informative markers were genotyped
in 2,860 INVEST patients to estimate Caucasian, African,
and Native American ancestry using STRUCTURE [15].
Race/ethnic groups were determined by patient self-report
with interaction by the study investigator [16] and con-
firmed using principal components analysis generated
from LD-pruned HumanCVD BeadChip data and ancestry
informative markers.
Statistical analysis
All statistical analyses were performed using SAS version
9.2 (SAS, Cary, NC). Differences in patient characteris-
tics comparing cases and controls at baseline were deter-
mined using t-tests and chi square tests, as appropriate.
Deviations from Hardy Weinberg Equilibrium were
assessed using a chi square test. Multi-variable logistic
regressions were performed overall and by race/ethnic
group to determine odds ratios (ORs) and 95% confi-
dence intervals (95%CIs) for type 2 diabetes in IVS5-
13insC variant carriers versus non-variant carriers. Vari-
ables for adjustment included age, gender, and body
mass index (BMI) in order to maintain consistency with
previously published HMGA1 analyses [5,7]. Percentage
of Caucasian, African, and Native American ancestry, as
estimated by ancestry informative markers, was included
as a variable for adjustment in analyses where all race/
ethnic groups were combined.
The combined race/ethnic group analysis was consid-
ered primary with alpha=0.05, since IVS5-13insC was
presumed to be a functional SNP with similar conse-
quences across race/ethnic groups, based on previously
published reports [5,7]. Assuming a MAF of 0.05 and
OR of 1.40, we had 84% power to detect an association
between the IVS5-13insC variant and type 2 diabetes in
a dominant model in the overall population. Assuming a
MAF of 0.05 and OR of 1.40, we had 61% power in His-
panics, 44% power in whites, and 18% power in blacks
to detect an association by race/ethnicity. Pairwise LD
values (r2) and LD plots were generated by race/ethnic
group using Haploview [17]. We predicted in silico func-
tional consequences of the IVS5-13insC variant using
SNPNexus [18] and ESEfinder 3.0 [19].
Results
We identified 446 incident type 2 diabetes cases over a
mean 2.8 years of follow-up and genotyped an additional
1329 prevalent type 2 diabetes cases in INVEST-GENES.At baseline, patients with incident or prevalent type 2 dia-
betes had higher BMI and lower diastolic BP versus age,
race/ethnicity, and gender-matched controls (Table 1).
Cases also had a higher prevalence of hypercholesterolemia,
left ventricular hypertrophy, and congestive heart failure.
The IVS5-13insC variant did not deviate from HWE in
any race/ethnic group (Table 2). All HMGA1 SNPs had
call rates above 95 percent and no SNPs failed quality con-
trol based on call rate, Hardy Weinberg equilibrium test-
ing, concordance with blind duplicates, or estimation of
heterozygosity using the inbreeding coefficient F. The gen-
omic inflation factor lambda was 1.03 for INVEST indivi-
duals genotyped for the HMGA1 IVS5-13insC variant,
suggesting minimal population stratification in genotyped
individuals. For the IVS5-13insC variant, concordance of
duplicates on TaqmanW was 99% and concordance be-
tween Pyrosequencing and TaqmanW was 95%. In Cauca-
sians, the MAF of IVS5-13insC was 0.03 in diabetic cases
and 0.04 in controls. The frequency of IVS5-13insC was
similar in African American individuals (0.03 in cases and
0.04 in controls) and highest in Hispanics (0.07 in cases
and 0.07 in controls). No significant associations were
observed between the IVS5-13insC variant and diabetes
overall (OR 0.98 95%CI 0.76-1.26, p=0.88). The IVS5-
13insC variant was not associated with diabetes in any
race/ethnic group (Table 2).
Pairwise LD of HMGA1 SNPs by race/ethnicity is pre-
sented in Figure 1. Pairwise LD (r2) of IVS5-13insC and
rs9394200, the SNP previously used as a tag SNP for
IVS5-13insC [7], was 0.47 in Caucasians, 0.25 in Hispa-
nics, 0.06 in African Americans. In silico functional ana-
lysis of IVS5-13insC revealed no predicted changes to
amino acid sequence, conserved transcription factor
binding sites, CpG islands, or miRNA regulatory sites.
IVS5-13insC was not predicted to cause the creation or
disruption of splice sites. However, in silico evaluation of
exonic splice enhancer (ESE) sites revealed that the C in-
sertion of IVS5-13insC creates an additional ESE motif
for SF2/ASF (IgM-BRCA1).
Discussion
In the present study, we observed that the HMGA1
IVS5-13insC variant was not associated with diabetes in
the INVEST-GENES population overall or in any race/
ethnic group. We observed a frequency of IVS5-13insC
consistent with previously published studies in Cauca-
sians [5,7] and observed an increased frequency of this
variant in Hispanics. Furthermore, pairwise LD in our
population suggests that IVS5-13insC is not effectively
tagged by rs9394200 in any race/ethnic group and in
silico analysis revealed minimal evidence of putative
functional consequences of the IVS5-13insC variant.
Our observations extend existing knowledge of genetic
determinants of type 2 diabetes and are consistent with
Table 1 Characteristics of type 2 diabetes cases and controls at baseline
Characteristic* Type 2 diabetes cases (n=1775) Controls (n=1295) p value†
Age (years) 65.8 (9.2) 65.7 (9.1) 0.93
Female, n (%) 1,014 (57) 731 (56) 0.71
BMI (kg/m2) 30.6 (5.6) 28.9 (5.4) <0.0001
Race/ethnicity, n (%) 0.15
Caucasian 608 (34) 493 (38)
Hispanic 937 (53) 642 (50)
African American 216 (12) 153 (12)
Blood pressure (mm Hg)
Systolic 149 (19) 148 (18) 0.32
Diastolic 85 (11) 86 (10) 0.0008
Hypercholesterolemia, n (%)‡ 1,017 (57) 673 (52) 0.003
History of LVH, n (%) 319 (18) 174 (13) 0.0007
History of CHF, n (%)** 84 (5) 25 (2) <0.0001
History of smoking, n (%) 706 (40) 507 (39) 0.73
BMI indicates body mass index; LVH, left ventricular hypertrophy; CHF, congestive heart failure.
*Values are mean ± standard deviation unless otherwise noted. †P values represent t-tests and chi square tests where appropriate. ‡History of or currently taking
lipid-lowering medications. **New York Heart Association Class I-III.
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association between IVS5-13insC and type 2 diabetes
[7]. Marquez et al. also found that the IVS5-13insC vari-
ant is not functional, which is supported by our lack of
observed association in multiple race/ethnic groups and
our in silico functional results which predicted no im-
portant consequences from this variability. Our findings
are inconsistent with two studies that observed a signifi-
cant association between IVS5-13insC and type 2 dia-
betes [5,6]. This discrepancy may be due to differences
in race/ethnicity of our population compared with other
studies. However, a functional IVS5-13insC variant
would be expected to have similar effects across multiple
race/ethnicity groups.
Although our association analysis is consistent with
the findings of Marquez et al. [7], our observation of low
LD between IVS5-13insC and rs9394200 in all race/Table 2 IVS5-13insC genotype frequencies and associations w
Race/ethnic group MAF (cases) MAF (controls) HWE p value
Overall 0.053 0.052 -
(n=3070)
Caucasian 0.028 0.036 0.40
(n=1101)
Hispanic 0.074 0.070 0.20
(n=1579)
African American (n=369) 0.030 0.039 0.10
95%CI indicates 95% confidence interval; MAF, minor allele frequency, HWE, Hardy
*Hardy Weinberg Equilibrium p value calculated using a chi square test by race/eth
dominant model adjusted for age, gender, body mass index, and Caucasian, Africanethnic groups suggests that rs9394200 is not an appro-
priate tag SNP for IVS5-13insC. In Hapmap, the MAF of
the T allele for rs9394200 is similar to the MAF for
IVS5-13insC in Caucasians (0.03), but is 0.45 in Yoru-
bans, further suggesting that rs9394200 does not ad-
equately tag IVS5-13insC, especially in non-Caucasian
populations. Furthermore, rs9394200 is 5000 base pairs
downstream from the of HMGA1 3′ end and is repre-
sented on arrays utilized by type 2 diabetes GWAS
[3,20]. Therefore, if rs9394200 were a significant con-
tributor to risk for diabetes, it likely would have been
identified in the GWAS analyses.
Our observation of a lack of association in Hispanics
and African Americans suggests that IVS5-13insC may be
associated with diabetes only in Caucasian individuals.
While we did not observe even a trend towards associ-
ation in our Caucasian population, we acknowledge thatith diabetes overall and by race/ethnicity
Unadjusted Adjusted
* Odds ratio (95%CI) p value Odds ratio (95%CI)† p value†
1.00 (0.79-1.26) 0.98 0.98 (0.76-1.26) 0.88
0.75 (0.46-1.22) 0.25 0.95 (0.44-2.06) 0.90
1.09 (0.82-1.45) 0.57 0.79 (0.49-1.25) 0.31
0.83 (0.36-1.90) 0.65 1.51 (0.48-4.74) 0.48
Weinberg Equilibrium.
nicity in non-diabetic patients. †Generated using logistic regression in a
, and Native American ancestry as estimated by ancestry informative markers.
Figure 1 Haploview-generated linkage disequilibrium (LD) plot of HMGA1 variation in INVEST Caucasians (A), Hispanics (B), and African
Americans (C). Regions of higher LD are shaded darker according to higher r2 values and pairwise r2 values are indicated in each box.
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lower than in the previously published studies. Although
we had 84 percent power to detect an association in
our overall population, we had inadequate power to
definitively conclude an association in by race/ethnicity
analyses.
Our in silico analysis did not reveal any direct mechan-
ism of the IVS5-13insC variant’s effects on mRNA expres-
sion or amino acid sequence, suggesting that the variant is
not likely to be functional. Although the results of Chiefari
et al. suggested a functional effect of the IVS5-13insC vari-
ant on HMGA1 and INSR mRNA and protein expression
in monocytes [5], Marquez et al. found no effect of the
variant on mRNA expression in adipose tissue. The differ-
ences in observed effect on mRNA expression may poten-
tially be explained by differential effects of the variant on
transcription in monocytes and adipose tissue. The appar-
ent functional effect of IVS5-13insC observed by Chiefari
et al. may also be confounded by the lack of evaluation of
IVS5-13insC variant carriers versus non-carriers among
non-diabetic controls [7] or potential treatment with
glucose-lowering medications in diabetic patients from
whom monocytes were collected [21]. Finally, IVS5-
13insC may have an unknown functional mechanism not
identified by in silico tools used in this study. Our study
has several limitations worthy of mention. We recognize
the potential for false negative results in our analyses, es-
pecially in African Americans, considering the low fre-
quency of the variant and the limited power to detect
associations within each race/ethic group. Our observa-
tions require replication in independent populations of
similar race/ethnic makeup. In INVEST, incident and
prevalent diabetes diagnosis was based on investigator
reports, but the diabetes phenotype is well described in a
previous publication [11], the accuracy of such reporting
has been verified by others [22], and has been used in
other trials [23-25]. INVEST investigator-reported dia-
betes phenotypes have also been used in a large scalegene-centric meta-analysis with HumanCVD BeadChip
data [26], suggesting validity with regard to the diabetes
phenotype and genetic association analysis. Although our
HMGA1 association analysis may be confounded if con-
trol patients eventually develop diabetes after study fol-
low-up, the high mean age and lower mean BMI suggests
that our control patients are less likely to develop type 2
diabetes. In addition, although concordance within the
TaqmanW genotyping platform was high, our concordance
between TaqmanW and Pyrosequencing was 95%, suggest-
ing some disagreement between platforms. However,
Hardy Weinberg tests did not indicate genotype error and
genotype error was minimized by utilization of Sanger se-
quencing for discrepancy confirmation.
Conclusions
Our results suggest that the HMGA1 IVS5-13insC is not
associated with type 2 diabetes and may not have an im-
portant functional role in diabetes pathogenesis. We also
provide frequency and LD data for Hispanic and African
American populations, which have higher prevalence of
type 2 diabetes. Our results also suggest that rs9394200
is not an effective tag SNP for HMGA1 IVS5-13insC, es-
pecially in non-Caucasian populations. Functional stud-
ies and replication of these associations are needed to
better define the potential role of HMGA1 variants in
predicting type 2 diabetes development. Although the
current study suggests the lack of a functional role for
IVS5-13insC, further study of HMGA1 is warranted to
clarify the role of this gene in diabetes pathogenesis. Lar-
ger, more adequately powered studies need to be per-
formed to confirm our findings.
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